European Journal of Neurology · 2005 · 15 citations · 38 references
Life SciencesImmunologyNeurologyClinical ImmunologyImmunotherapyNeuroimmunologyAdaptive Immune ResponsesAutoimmune DiseasesAutoimmune Neurological DisordersMultiple SclerosisMultiple Sclerosis PharmacotherapyNeuroinflammationImmunological AssaysImmunological BiomarkersMultiple Sclerosis ImmunopathologyMultiple Sclerosis TherapyProliferation AssaysRelapsing-remitting Multiple Sclerosis TreatmentTreatment Response Biomarkers
Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.
38
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations
Pharmacy, Neurology, Pharmacotherapy +15
Bibiana Bielekova, Bonnie L. Goodwin, Nancy Richert et al. · Nature Medicine · 2000 · 826 citations
Giancarlo Comi, Massimo Filippi, Jerry S. Wolinsky · PubMed · 2001 · 691 citations
Pharmacy, Neurology, Pharmacotherapy +14
Giancarlo Comi, Massimo Filippi, Jerry S. Wolinsky · Annals of Neurology · 2001 · 608 citations
Medicine, Neurology, Pharmacotherapy +15